NIKKEI 225
26,739.03 +336.19 (+1.27%) HANG SENG
20,717.24 +596.56 (+2.96%) CRUDE OIL
110.35 +0.46 (+0.42%) GOLD FUTURES
1,845.10 +3.90 (+0.21%) DOW
31,261.90 +8.77 (+0.03%) BTC-GBP
23,588.64 -254.99 (-1.07%)
MorphoSys AG (MOR.DE)
| Previous close | 19.09 |
| Open | 19.09 |
| Bid | 19.52 x 1500 |
| Ask | 19.55 x 8800 |
| Day's range | 18.90 - 19.99 |
| 52-week range | 16.45 - 72.84 |
| Volume | |
| Avg. volume | 240,415 |
| Market cap | 670.188M |
| Beta (5Y monthly) | 0.85 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
MorphoSys AG Reports Outcome of Annual General Meeting 2022
DGAP-News: MorphoSys AG / Key word(s): AGM/EGMMorphoSys AG Reports Outcome of Annual General Meeting 2022 18.05.2022 / 22:02 The issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, May 18, 2022MorphoSys AG Reports Outcome of Annual General Meeting 2022All Proposed Resolutions ApprovedMorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its shareholders approved all resolutions proposed by the Company´s Management and Supervisory Boards at
- EQS Group
MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual Meetings
DGAP-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual Meetings 12.05.2022 / 16:45 The issuer is solely responsible for the content of this announcement.Media ReleaseBOSTON, Mass., USA, May 12, 2022MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EH
- EQS Group
MorphoSys AG Reports First Quarter 2022 Financial Results
DGAP-News: MorphoSys AG / Key word(s): Quarterly / Interim StatementMorphoSys AG Reports First Quarter 2022 Financial Results 04.05.2022 / 22:01 The issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, May 4, 2022MorphoSys AG Reports First Quarter 2022 Financial Results- Monjuvi® U.S. net product sales of US$ 18.7 million (€ 16.6 million) for the first quarter 2022, a 21% year-over-year growth- NCCN® updated the designation of Monjuvi to preferr
